Supplementary Figure S3 from The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

• DOI: 10.1158/1078-0432.25826583.v1
• Publication Date: 2024-05-15T07:43:22Z
• Authors: Eranga R. Balasoo...; Qibiao Wu; Haley Ellis; Yuanli Zhen; Bryanna L. Norden; Ryan B. Corcoran; Adithi Mohan; Eric Martin; Aleksandra Franovic; John Tyhonas; Matthew Lardy; Kathryn B. Grandi...; Robert Pelham; Liliana Soroceanu; Vanessa S. Silveira; Nabeel Bardeesy
• Keywords: Protein kinase domain

<p>Supplementary Figure S3. Treatment with KIN-3248 is well-tolerated when administered orally at doses up to 15 mg/kg daily. Data are from the CCLP-1 model engineered FGFR2-PHGDH fusion (n=8 mice/group) and presented as mean ± SEM.</p>